glp-1 agonists brand names are commonly used medications to treat Type 2 Diabetes. They are subcutaneous injections, so many patients mistaken these medications for insulin. However, GLP-1's are very different. They work primarily on GLP-1 Receptor Agonists - Complete

While newly approved pharmacotherapies such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) show efficacy, their clinical utility remains constrained by dose-dependent gastrointestinal complications, underscoring the urgent need for safer alternatives

Neurodegenerative diseases, including Alzheimers Disease (AD) and Parkinsons Disease (PD) are common complications of diabetes, arising from insulin resistance, inflammation, and other pathological processes in the central nervous system

GLP-1R agonist 2 has the potential for research in metabolic diseases such as type 2 diabetes and obesity

Berberine is not a GLP-1 agonist, though both compounds influence metabolic pathways